Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

Low Back Pain Clinical Trial

Official title:

Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus a Combination of Tapentadol PR and Pregabalin in Subjects With Severe Chronic Low Back Pain With a Neuropathic Pain Component

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01352741
• Other study ID #: 247251
• Secondary ID: 2010-019998-14KF
• Status: Completed
• Phase: Phase 4
• Start date: March 2011
• Est. completion date: January 2012

Study information

• Verified date: October 2019
• Source: Grünenthal GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the study is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a combination of tapentadol PR (300 mg per day) and pregabalin (to 300 mg per day) in subjects requiring additional analgesia after titration to tapentadol PR 300 mg per day.

This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject reported outcomes. Since, severe low back pain with a neuropathic component, the targeted study population, is frequently treated with a combination therapy (monotherapy is often not effective enough) it is of interest to determine if tapentadol alone (combining 2 mechanisms of action in a single molecule) could be as effective as a combination of tapentadol plus pregabalin. Furthermore, the tolerability profiles of monotherapy versus combination are of interest.

Description:

Participants with a diagnosis of chronic low back pain (defined as pain lasting for at least 3 month) and requiring a strong analgesic (World Health Organization [WHO] Step III) as judged by the investigator and having a positive or unclear score using the painDETECT diagnostic screening questionnaire will enter the open-label titration tapentadol prolonged release (PR) period. In total participants will have 11 planned scheduled visits scheduled over 105 days. At the Enrollment Visit [Day -14 (3 to 14 days prior to the Baseline Visit)] the inclusion and exclusion criteria will be checked to evaluate the participant's eligibility for the trial. Participants on previous analgesics will start a washout period three days up to 2 weeks.The duration of the washout period will depend on previous opioid analgesics and co-analgesics and their respective doses, down-tapering steps. Participants who do not need a washout of previous analgesic treatment (e.g. WHO Step I analgesics), a baseline visit can be scheduled as soon as clinical laboratory monitoring results are available.

At the Baseline Visit (Day 1) participants will start the 3 week open-label titration period tapentadol prolonged release (PR) at doses of 2 x 50 mg per day and will be titrated upwards in steps of 100 mg (2 x 50 mg) on a weekly basis.

Participants who do not qualify for randomization may continue the trial in the open-label continuation arm if they have already reached a satisfactory level of pain relief.

Participants qualifying for randomization in the comparative period (Day 22 to 77) will be allocated to 1 of 2 treatment arms and will continue treatment.

Either they continue on tapentadol prolonged release (PR) with increasing doses of tapentadol PR

• After the randomization visit, participants will titrate up to a total daily dose of 400 mg.

• 1 week after the randomization visit, will titrate up to a total daily dose of 500 mg. Participants in this treatment arm will receive a final dose of 500 mg tapentadol PR per day.

Or start on a combination of tapentadol PR 300 mg per day with pregabalin

• After the randomization visit, participants will continue their previous regimen of tapentadol PR 2 x 150 mg per day plus pregabalin 2 x 75 mg (total daily dose of 150 mg pregabalin).

• 1 week after the randomization visit, participants will continue their previous regimen (end of titration period) of tapentadol PR 2 x 150 mg per day plus pregabalin 2 x 150 mg (total daily dose of 300 mg pregabalin). Participants in this treatment arm will receive a final dose of 300 mg tapentadol PR and 300 mg pregabalin.

Participants in the Comparative Period can be assigned to the open-label pick-up arm and will be treated with a stable dose of tapentadol PR 300 mg per day or 400 mg per day if they experience treatment emergent adverse events (at least possibly related to investigational medicinal product).The open-label pick-up period theoretically starts on Day 29, i.e. one week after the Randomization Visit.

The Final Evaluation (Day 77) is planned to take place 8 weeks after randomization.

After the Final Evaluation a Follow-up Period (blinded tapering down/out of IMP in Week 12 and Follow-up Visit (up to Day 91) will take place. Tapering down/out of medication will be performed according to the Summary of Product Characteristics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 622
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have a diagnosis of chronic low back pain; chronic pain defined as pain lasting for at least 3 months.

• Subject's pain must require a strong analgesic (defined as World Health Organization (WHO) step III) as judged by the investigator.

• The painDETECT diagnostic screening questionnaire score must be:

• "positive" or

• "unclear".or If the subject is being treated with a stable regimen of centrally acting analgesics (opioids) and/or co-analgesics, even a "negative" painDETECT score (but of at least 9) at the enrollment visit will be acceptable.

• If under regular daily pretreatment with a WHO step II/step III opioid analgesic and/or a centrally acting co-analgesic:

• Subjects must be taking a WHO step II or step III analgesic or co- analgesic on a daily basis for at least 2 weeks prior to the enrollment visit.

• Subjects pretreated with a WHO step II opioid analgesic and/or a centrally acting co-analgesic must have reported an average pain intensity score of at least 5 points (NRS-3=5) during the last 3 days prior to the enrollment visit. or If under regular, daily pretreatment with a WHO step I analgesic monotherapy or if no regular analgesic pretreatment is reported:

• Subjects must have an average pain intensity score of at least 6 points NRS-3=6) in the last 3 days prior to the enrollment visit.

Exclusion Criteria:

• Presence of concomitant painful conditions other than low back pain that could confound the subject's trial assessments or self-evaluation of the index pain, e.g., syndromes with widespread pain such as fibromyalgia.

• Low back pain caused by cancer and/or metastatic diseases.

• Any painful procedures planned during the trial period (e.g., major surgery) that may, in the opinion of the investigator, affect the effectiveness or safety assessments of the Investigational Medicinal Product (IMP).

• Pending litigation or application for insurance/governmental benefits due to chronic pain or disability and, if granted, benefits might be influenced by a successful participation in the trial.

• Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, lactose intolerance.

Related Conditions & MeSH terms

• Back Pain
• Low Back Pain
• Neuralgia
• Neuropathic Pain

Intervention

Drug:
• Tapentadol Prolonged Release
100 - 500 mg per day orally twice daily for a maximum of 12 weeks
• Tapentadol Prolonged Release with Pregabalin
Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
• Tapentadol Prolonged Release open label maintenance
100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily

Locations

Country	Name	City	State
Austria	Site 506	Klagenfurt
Austria	Site 503	Senftenberg
Austria	Site 501	Wien
Austria	Site 502	Wien
Austria	Site 504	Wien
Austria	Site 505	Wien
Belgium	Site 605	Dour
Belgium	Site 602	Genk
Belgium	Site 603	Gozee
Belgium	Site 604	Ham
Belgium	Site 601	Pellenberg
Denmark	Site 702	Copenhagen
Denmark	Site 704	Frederiksberg
Denmark	Site 701	Glostrup
Denmark	Site 703	Ringsted
Germany	DE 118	Berlin
Germany	Site 107	Berlin
Germany	Site 111	Böhlen
Germany	Site 115	Cottbus
Germany	Site 103	Hamburg
Germany	Site 110	Hamburg
Germany	Site 101	Kiel
Germany	Site 114	Kiel
Germany	Site 105	Köln
Germany	Site 116	Köln
Germany	Site 113	Leipzig
Germany	Site 109	Lübeck
Germany	Site 106	Rendsburg
Germany	Site 108	Schönau
Germany	Site 117	Weimar
Germany	Site 112	Westerstede
Germany	Site 104	Wiesbaden
Netherlands	Site 803	Amsterdam
Netherlands	Site 804	Eindhoven
Netherlands	Site 805	Enschede
Netherlands	Site 802	Heerenveen
Netherlands	Site 801	Sliedrecht
Poland	Site 309	Bydgoszcz
Poland	Site 312	Gdansk
Poland	Site 303	Katowice
Poland	Site 308	Krakow
Poland	Site 310	Krakow
Poland	Site 311	Krakow
Poland	Site 307	Lublin
Poland	Site 306	Ostrów Mazowiecka
Poland	Site 304	Poznan
Poland	Site 301	Warsaw
Poland	Site 302	Warszawa
Poland	Site 305	Wroclaw
Spain	Site 904	A Coruna
Spain	Site 908	Alicante
Spain	Site 901	Badalona
Spain	Site 905	Barcelona
Spain	Site 902	Centelles
Spain	Site 907	Granada
Spain	Site 909	Madrid
Spain	Site 910	Madrid
Spain	Site 903	Oviedo
Spain	Site 911	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Grünenthal GmbH

Countries where clinical trial is conducted

Austria,  Belgium,  Denmark,  Germany,  Netherlands,  Poland,  Spain, 

References & Publications (2)

Baron R, Kern U, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Ran — View Citation

Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic C — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Average Pain Intensity Score for the Overall Low Back Pain on an 11-point Numeric Rating Scale (NRS-3)	The primary endpoint is defined as the comparison of tapentadol prolonged release (PR) 300 mg plus 200 mg per day and the combination of tapentadol PR 300 mg per day and pregabalin 300 mg per day regarding the change in NRS-3 pain intensity scores (recalled average pain intensity score during the last 3 days on 11-point NRS, where 0 is the no pain and 10 is pain as bad as you can imagine) from the randomization visit to the final evaluation visit.; Theoretically a maximum decrease of -10 and an increase of +4 in the pain intensity would have been possible. A negative sign indicates a decrease in pain intensity from the start of treatment. The higher the absolute values, the greater the change since the start of treatment (Baseline visit).	Randomization (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Average Pain Intensity Score for the Overall Low Back Pain on an 11-point Numeric Rating Scale (NRS-3)	The recalled average pain intensity score on the NRS-3 was assessed using an 11-point Numeric Rating Scale (NRS). This scale recalls the average pain intensity during the last 3 days. The participant was asked: "Please rate your pain intensity by assessing the one number that best describes your pain on average during the last 3 days (the last 72 hours prior to the visit)". Where 0 = no pain and 10 indicates pain as bad as you can imagine. This is the treatment period prior to the primary outcome period.	Enrollment (Day -14); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Continuation Period: Average Pain Intensity Score for the Overall Low Back Pain on an 11-point Numeric Rating Scale (NRS-3)	The recalled average pain intensity score on the NRS-3 was assessed using an 11-point Numeric Rating Scale (NRS). This scale recalls the average pain intensity during the last 3 days. The participant was asked: "Please rate your pain intensity by assessing the one number that best describes your pain on average during the last 3 days (the last 72 hours prior to the visit)". Where 0 = no pain and 10 indicates pain as bad as you can imagine.	Enrollment (Day -14); Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	End of Open-label Pick-up Period: Average Pain Intensity Score for the Overall Low Back Pain on an 11-point Numeric Rating Scale (NRS-3)	The recalled average pain intensity score on the NRS-3 was assessed using an 11-point Numeric Rating Scale (NRS). This scale recalls the average pain intensity during the last 3 days. The participant was asked: "Please rate your pain intensity by assessing the one number that best describes your pain on average during the last 3 days (the last 72 hours prior to the visit)". Where 0 = no pain and 10 indicates pain as bad as you can imagine.	Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Radiating Pain	The NRS-3 pain intensity score at the visits in the open-label titration period for the two comparative double-blind period treatment groups analyzed is reported. NRS-3 pain intensity score (recalled average pain intensity score during the last 3 days on an 11-point NRS) for radiating pain (pain radiating into or towards the leg, typically of shooting, radiating character, usually radiating below the knee towards the foot) is reported. Where 0 = no pain and 10 indicates pain as bad as you can imagine.	Enrollment Visit (Day -14); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Radiating Mean Pain Intensity Score for the Comparative Period Population	The NRS-3 pain intensity score at the visits in the open-label titration period for the two comparative double-blind period treatment groups analyzed is reported. NRS-3 pain intensity score (recalled average pain intensity score during the last 3 days on an 11-point NRS) for radiating pain (pain radiating into or towards the leg, typically of shooting, radiating character, usually radiating below the knee towards the foot) is reported. Where 0 = no pain and 10 indicates pain as bad as you can imagine.	Enrollment Visit (Day -14); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in NRS-3 Pain Intensity Score for the Radiating Pain	NRS-3 pain intensity score (recalled average pain intensity score during the last 3 days on 11-point NRS, where 0 is the no pain and 10 is pain as bad as you can imagine) for radiating pain (pain radiating into or towards the leg, typically of shooting, radiating character, usually radiating below the knee towards the foot).; The value reported represents the change from the randomization visit (i.e., the last 3 days in the titration period) to the end of the double-blind comparative period (i.e., the last 3 days in the comparative period). The theoretical values range from -10 to 10. A negative sign indicates a decrease in pain from the start of treatment. The higher the absolute values, the greater the change since the start of treatment (baseline visit).	Randomization Visit (Day 22); End of Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Worst Mean Pain Intensity Scores Over the Past 24 Hours	The recalled worst pain intensity during the last 24 hours was assessed using an 11-point Numeric rating scale, where 0 = no pain and 10 = pain as bad as you can imagine.; The participant was asked: "Please rate your pain intensity by assessing the one number that best describes your worst pain during the last 24 hours prior to the visit".	Enrollment Visit (Day -14); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Comparative Double-blind Period Population Worst Mean Pain Intensity Scores Over the Past 24 Hours	The recalled worst pain intensity during the last 24 hours was assessed using an 11-point Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "pain as bad as you can imagine".; The participant was asked : "Please rate your pain intensity by assessing the one number that best describes your worst pain during the past 24 hours prior to the visit".	Enrollment Visit (Day-12); Baseline Visit (day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in Worst Pain Intensity Over the Past 24 Hours	The recalled worst pain intensity during the last 24 hours was assessed using an 11-point Numeric rating scale, where 0 = no pain and 10 = pain as bad as you can imagine.; The participant was asked: "Please rate your pain intensity by assessing the one number that best describes your worst pain during the last 24 hours prior to the visit".; A negative change indicates that the pain intensity decreased from the start of the trial.	Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: painDETECT Assessments	The painDETECT was a participant completed questionnaire. The questionnaire consists of 14 questions in four domains. Based on these questions a final assessment score was calculated. The minimum score ranged from zero to a maximum of 38. Participants with a score between 0 and 12 were scored as being "negative" (had no neuropathic pain component). A value between 19 and 38 was rated as being "positive" (neuropathic component present). Values from 13 to 18 were scored as being "unclear".	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Comparative Double-blind Period Population painDETECT Assessment	The painDETECT was a participant completed questionnaire. The questionnaire consists of 14 questions in four domains. Based on these questions a final assessment score was calculated. The minimum score ranged from zero to a maximum of 38. Participants with a score between 0 and 12 were scored as being "negative" (had no neuropathic pain component). A value between 19 and 38 was rated as being "positive" (neuropathic component present). Values from 13 to 18 were scored as being "unclear".	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in painDETECT Final Assessment	The painDETECT was a participant completed questionnaire. The questionnaire consists of 14 questions in four domains. Based on these questions a final assessment score was calculated. The minimum score ranged from zero to a maximum of 38. Participants with a score between 0 and 12 were scored as being "negative" (had no neuropathic pain component). A value between 19 and 38 was rated as being "positive" (neuropathic component present). Values from 13 to 18 were scored as being "unclear". The theoretical range of change in this trial ranged from -38 to 19. A negative change indicated a decrease in their neuropathic component of pain.	Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Neuropathic Pain Symptom Inventory (NPSI) Overall Score Assessment	In the Neuropathic Pain Symptom Inventory (NPSI) the participant rated their symptoms of neuropathic pain. Ten pain questions were answered on an 11-point scale; from 0 (symptom not present) to 10 (symptom at its worst imaginable intensity, e.g. worst burning imaginable). The overall NPSI score was calculated by the summation of all ten responses and ranges between 0 and 100. For pain descriptions burning, pressing, paroxysmal (pain like electric shocks or stabbing), evoked (due to touch) and paresthesia (sensation that is not unpleasant) or dysesthesia (unpleasant) sub-scores are reported. The overall values reported for all participants that completed the questionnaire are shown. A symptom was absent if the value is 0, the symptom was present in all participants and all participants rated it at its worst possible intensity if a value is 100.	Enrollment Visit; Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Neuropathic Pain Symptom Inventory (NPSI) Overall Score Assessment in the Double-blind Comparative Period Population	In the Neuropathic Pain Symptom Inventory (NPSI) the participant rated their symptoms of neuropathic pain. Ten pain questions were answered on an 11-point scale; from 0 (symptom not present) to 10 (symptom at its worst imaginable intensity, e.g. worst burning imaginable). The overall NPSI score was calculated by the summation of all ten responses and ranges between 0 and 100. For pain descriptions burning, pressing, paroxysmal (pain like electric shocks or stabbing), evoked (due to touch) and paresthesia (sensation that is not unpleasant) or dysesthesia (unpleasant) sub-scores are reported. The overall values reported for all participants that completed the questionnaire are shown. A symptom was absent if the value is 0, the symptom was present in all participants and all participants rated it at its worst possible intensity if a value is 100.	Enrollment Visit; Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Double-blind Comparative Period: Change in Neuropathic Pain Symptom Inventory (NPSI) Sub-scores and Overall Score Assessment	In the Neuropathic Pain Symptom Inventory (NPSI) the participant rated their symptoms of neuropathic pain. Ten pain questions were answered on an 11-point scale, from 0 (symptom not present) to 10 (symptom at its worst imaginable intensity, e.g. Spontaneous Pressing Pain Subscore). The overall NPSI score was calculated by the summation of all ten responses and ranges between 0 and 100. For pain descriptions burning, pressing, paroxysmal (pain like electric shocks or stabbing), evoked (due to touch) and paresthesia (sensation that is not unpleasant) or dysesthesia (unpleasant) subscores are reported. The overall values reported for all participants that completed the questionnaire are shown. A symptom was absent if the value is 0, the symptom was present in all participants and all participants rated it at its worst possible intensity if a value is 10 (100 for the overall score) . A negative change indicates that the intensity of the symptom has decreased since the start of treatment.	Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Comparative Double-blind Period Population Short Form Health Survey (SF-12) Physical Health Composite Score (PCS)	The Short Form Health Survey (SF-12) has several brief broad questions on 8 aspects of health (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. The physical and mental summary scores were calculated from the individual responses. A higher score indicates a better perceived state of health. All domains were scored on a scale from 0 (lowest level of health) to 100 (highest level of health), with 100 representing the best possible health state.	Enrollment Visit; Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Changes in the Short Form Health Survey (SF-12) Physical Health Composite Score (PCS)	The Short Form Health Survey (SF-12) has several brief broad questions on 8 aspects of health (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. The physical summary scores were calculated from the individual responses to those questions covering physical health. A higher score indicates a better participant perceived state of health. All domains were scored on a scale from 0 (lowest level of health) to 100 (highest level of health), with 100 representing the best possible health state.; The change in the SF-12 score shows an improvement in health from baseline if the values are positive. The higher the value the greater the improvement.	Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Comparative Double-blind Period Population Short Form Health Survey (SF-12) Mental Health Composite Score (MCS)	The Short Form Health Survey (SF-12) has several brief broad questions on 8 aspects of health (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. The mental health summary scores were calculated from the individual responses to two of the 12 questions. A higher score indicates a better participant perceived state of health. All domains were scored on a scale from 0 (lowest level of health) to 100 (highest level of health), with 100 representing the best possible mental health.	Enrollment Visit; Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in Short Form Health Survey (SF-12) Mental Health Composite Score (MCS)	The Short Form Health Survey (SF-12) has several brief broad questions on 8 aspects of health (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. The mental health summary scores were calculated from the individual responses to two of the 12 questions. A higher score indicates a better participant perceived state of health. All domains were scored on a scale from 0 (lowest level of health) to 100 (highest level of health), with 100 representing the best possible mental health.	Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: EuroQol-5 Dimension (EQ-5D) Health Status Index Score for the Double-blind Comparative Period Population	The participant scored the EuroQol-5 questionnaire. The EuroQol-5 questionnaire uses a health state classification with 5 dimensions. Each dimension was assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1 (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1) the better the health status in a treatment group.	Enrollment Visit (day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change EuroQol-5 Dimension (EQ-5D) Health Status Index	The participant scored the EuroQol-5 questionnaire. The EuroQol-5 questionnaire uses a health state classification with 5 dimensions. Each dimension was assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1 (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1) the better the health status in a treatment group.	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Patient Global Impression of Change (PGIC)	In the Patient Global Impression of Change (PGIC) the participant indicated the perceived change over the treatment period. PGIC is a 7 point scale where the patient's rates overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."	Randomization Visit (Day 22) to Final Evaluation Visit (Day 77)
Secondary	Double-blind Comparative Period: Clinician Global Impression of Change (CGIC)	In the Clinician Global Impression of Change (CGIC) the clinician indicated the perceived change over the treatment period. The clinician was requested to choose one of seven categories for each participant. The Clinician rated the participants change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."	Randomization Visit (Day 22) to Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Hospital Anxiety and Depression Scale - Anxiety in the Double-blind Comparative Period Population	The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises 14 items. Seven statements describe anxiety. Each answer is scored on a four-point scale (0-3). All seven answers are summed to a total score with a maximum score of 21 points. A score below 7 is not considered to indicate anxiety. A score of 11 or above is considered to be a case of anxiety.; A decrease in values over the trial period indicate that there has been an improvement.	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in Hospital Anxiety and Depression Scale - Anxiety in the Double-blind Comparative Period Population	The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises 14 items. Seven statements describe anxiety. Each answer is scored on a four-point scale (0-3). All seven answers are summed to a total score with a maximum score of 21 points. A score below 7 is not considered to indicate anxiety. A score of 11 or above is considered to be a case of anxiety.; A negative sign indicates that there has been a decrease in anxiety since the start of treatment.	Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Hospital Anxiety and Depression Scale - Depression in the Double-blind Comparative Period Population	The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises 14 items. Seven statements describe depression. Each answer is scored on a four-point scale (0-3). All seven answers are summed to a total score with a maximum score of 21 points. A score below 7 is not considered to indicate depression. A score of 11 or above is considered to be a case of depression. A decrease in values over time indicates that there has been an improvement.	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in Hospital Anxiety and Depression Scale - Depression in the Double-blind Comparative Period Population	The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises 14 items. Seven statements describe depression. Each answer is scored on a four-point scale (0-3). All seven answers are summed to a total score with a maximum score of 21 points. A score below 7 is not considered to indicate depression. A score of 11 or above is considered to be a case of depression. A decrease in values over time indicates that there has been an improvement. A negative change value indicates a decrease in the depression score since the start of treatment.	Baseline Visit (Day 1); Randomization Visit (Day 22); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Latency	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the sleep latency.; To assess latency the participant was asked: How long after bedtime/lights out did you fall asleep last night [hours]?	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Latency in the Double-blind Comparative Period Population	The sleep evaluation questionnaire was completed by the participant. The participant was asked: How long after bedtime/lights out did you fall asleep last night [hours]? The values are for the night prior to the Randomization Visit (Baseline) and for the night prior to the Final Evaluation Visit (12 weeks after randomization). The higher the value the longer it took to fall asleep. Sleep evaluation questionnaire (SQ) items	Enrollment Visit (Day -12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period Sleep Evaluation Questionnaire: Change in Latency	The sleep evaluation questionnaire was completed by the participant. The participant was asked: How long after bedtime/lights out did you fall asleep last night [hours]? The values are for the night prior to the visits. The negative change from baseline indicates that the time to falling asleep decreased from baseline in a treatment group.	Baseline Visit (Day 1); Randomization Visit (Day 22) to Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Number of Awakenings	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the number of awakenings.; How many times did you wake up during the night? The values were calculated from the data that participants self-reported for the night prior to their Randomization Visit (Baseline), for the night prior to the Baseline Visit (Day 1) and the night prior to the Randomization Visit (Day 22).; The participant was asked at each visit: "How many times did you wake up during the night?"	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Sleep Evaluation - Number of Awakenings in the Double-blind Comparative Period Population	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the number of awakenings.; How many times did you wake up during the night? The values were calculated from the data that participants self-reported for the night prior to their Randomization Visit (Baseline), for the night prior to the Baseline Visit (Day 1) and the night prior to the Randomization Visit (Day 22).; The participant was asked at each visit: "How many times did you wake up during the night?"	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in the Number of Awakenings	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the number of awakenings. Participants were asked: How many times did you wake up during the night? The change in the Number of Awakenings was calculated from the data that participants self-reported for the night prior to their Randomization Visit (Baseline), for the night prior to the Baseline Visit (Day 1) and the night prior to the Final Evaluation Visit (Day 77). A negative change indicates that the number of awakenings in a treatment group have gone down since the Baseline or Randomization Visit. In general pain can interfere with sleep, one potential indicator is the number of awakenings.	Baseline Visit (Day 1); Randomization Visit (Day 22) to Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Time Slept	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the number of awakenings.; The participant was asked: "How long did you sleep last night?" [Answered in hours and minutes].	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Number of Hours Slept in the Double-blind Comparative Period Population	The participants were requested to answer the following question: How long did you sleep last night [hours]? The values were calculated from the data that participants self-reported for the night prior to their Randomization Visit (Baseline) and for the night prior to the End of the Continuation Visit (12 weeks after randomization).	Enrollment Visit (Day -12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Sleep Evaluation Questionnaire - Change in the Number of Hours Slept	The sleep evaluation questionnaire was completed by the participant. The answer was in response to the question: Sleep evaluation: How long did you sleep last night [hours]? The value reported is the change in the number of hours of sleep from baseline. The positive value indicates that there was an increase in the number of hours of sleep in a treatment group.	Baseline Visit (Day -12); Randomization Visit (Day 1); Final Evaluation Visit (Day 77)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Overall Quality of Sleep	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the overall quality of sleep.; The participant rated this categorically as being one of the following: excellent, good, fair or poor.	Enrollment Visit (Day-12); Baseline Visit (Day 1); Randomization Visit (Day 22)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Overall Quality of Sleep in the Double-blind Comparative Period Population	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the overall quality of sleep.; The participant rated this categorically as being one of the following: excellent, good, fair or poor.	Enrollment Visit (Day-12)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Overall Quality of Sleep in the Double-blind Comparative Period Population	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the overall quality of sleep.; The participant rated this categorically as being one of the following: excellent, good, fair or poor.	Baseline Visit (Day 1)
Secondary	Open-label Titration Period: Sleep Evaluation Questionnaire - Overall Quality of Sleep in the Double-blind Comparative Period Population	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the overall quality of sleep.; The participant rated this categorically as being one of the following: excellent, good, fair or poor.	Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Change in the Overall Quality of Sleep	The sleep evaluation questionnaire was completed by the participant. The questionnaire measures 4 main concepts: 1 of the 4 main concepts being the overall quality of sleep.; The improvement, no change or worsening is reported based on the replies scored by the participants given at their End of Continuation Visit.	Randomization Visit (Day 22) to Final Evaluation (Day 77)
Secondary	Open-label Titration Period: Subject's Satisfaction With Treatment	Participants rated their satisfaction with the study drug (IMPs) by answering the following question on a 5-point rating scale: "How would you rate your overall satisfaction with your current pain treatment?": Excellent, Very Good, Good, Fair and Poor.	End of Open-label Titration Period at Randomization Visit (Day 22)
Secondary	Double-blind Comparative Period: Subject's Satisfaction With Treatment	Participants rated their satisfaction with the study drug (IMPs) by answering the following question on a 5-point rating scale: "How would you rate your overall satisfaction with your current pain treatment?": Excellent, Very Good, Good, Fair and Poor.	End of Comparative Period at Final Evaluation Visit (Day 77)